News

SK Life Science Celebrates New Insights from C035 Study

SK Life Science Celebrates New Insights from C035 Study

SK Life Science Unveils Critical Research Findings

SK Life Science, Inc., a pioneering name in the realm of treatments for central nervous system (CNS) disorders, has announced the publication of groundbreaking studies that reveal new insights into the efficacy and safety of adjunctive cenobamate for adult patients grappling with uncontrolled focal seizures. The research detailed in these publications stems from the C035 study, a comprehensive trial conducted across several Asian countries, including China and Japan. This vital study significantly enriches existing clinical evidence supporting the use of cenobamate.

Understanding the Implications of the C035 Study

Dr. Sunita N. Misra, who serves as the Senior Vice President of Clinical Development and Medical Affairs at SK Life Science, articulated the significance of these publications. She stated, "These publications represent important progress in our understanding of cenobamate's clinical profile. The findings from this study provide additional information regarding cenobamate's efficacy across seizure types and patient groups." This sentiment highlights a growing confidence in cenobamate as a potential solution for individuals facing challenging seizure management.

Published Research Overview

The articles made available through esteemed journals like Epilepsia and Seizure provide a closer look at how cenobamate performs in varied patient populations. The articles include:

  • A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of adjunctive cenobamate in Asian patients with focal seizures by Lee et al. published in Epilepsia.
  • Early response rates with adjunctive cenobamate in uncontrolled focal seizures: prospective analysis of a randomized, double-blind, placebo-controlled study in a multinational Asian population by Kawai et al. also in Epilepsia.
  • Efficacy of adjunctive cenobamate by focal seizure subtypes: a randomized, double-blind placebo-controlled study in a multinational Asian population by Wu et al. featured in Seizure.

About SK Life Science, Inc.

Headquartered in Paramus, New Jersey, SK Life Science, Inc. is a vital entity within the SK Biopharmaceuticals Co., Ltd. framework. This collaboration is dedicated to delivering innovative therapies for CNS disorders and oncology through rigorous drug development processes. Currently, a total of ten compounds are under development, showcasing the commitment to enhancing patient care through scientific breakthroughs.

Focused Innovation and Global Outreach

SK Life Science is heavily involved in various drug discovery methodologies, including high-throughput organic screening, pharmacology, and clinical development, all aimed at addressing critical healthcare needs. With a footprint extending beyond the U.S., the company collaborates with various partners to ensure the broad availability of cenobamate across different global markets.

Understanding XCOPRI® (cenobamate tablets)

Cenobamate is a novel antiseizure medication designed to reduce neuronal excitability, exhibiting a unique mechanism of action that involves inhibiting persistent sodium currents and enhancing GABAergic inhibition. With its approval in the U.S. under the brand name XCOPRI®, it is a significant advancement for those living with epilepsy, offering new hope where traditional treatments may have fallen short.

Expanding Treatment Options for Epilepsy

This publication marks a crucial step toward broadening treatment options for epilepsy, a disorder that affects millions worldwide. Despite various existing therapies, many individuals do not achieve full seizure control. The findings from the C035 study could lead to improved outcomes for countless patients.

Frequently Asked Questions

What is the significance of the C035 study?

The C035 study provides critical evidence regarding the efficacy and safety of adjunctive cenobamate in managing uncontrolled focal seizures among diverse patient populations.

Who conducted the C035 study?

The study was sponsored by SK Life Science, Inc. and involved several clinical sites across Asia, including Japan, China, and the Republic of Korea.

What does cenobamate treat?

Cenobamate is indicated for treating partial-onset seizures in adults aged 18 years and older living with epilepsy.

How does cenobamate work?

Cenobamate enhances GABAergic inhibition while inhibiting persistent sodium currents in neuronal activity, which helps reduce seizures.

How can I find more information about SK Life Science?

Interest in SK Life Science and its products can be explored through its official website, which provides detailed information on ongoing studies and product offerings.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Alley Cat Allies Pushes for Humane Cat Conservation Bill

Updated Category News Views 70

Time to Rethink Conservation: Save the Cats If you’re tuned into the chatter buzzing around the Cayman Islands, you know the clocks are ticking for a decision that could change the approach to handling community cats. Alley Cat Allies is waving the flag, urging the Cayman Islands Parliament to pass a bill that abandons the archaic practice of culling cats by shooting...

Continue Reading
Luxury Villa Cashback Offers Entice Travelers in November

Updated Category News Views 134

A November Bonanza for Villa Bookings Who doesn't love having a few extra bucks in their pocket, especially when they come with the allure of luxury travel? Villas of Distinction is rolling out what they call a 'November Cashback Offer,' and for those with the wallet—and wanderlust—to match, it could be a tempting proposition. Hanging the bait of up to $2,000 cashback...

Continue Reading
Duolingo Faces Class Action: Key Investor Steps

Updated Category News Views 126

Navigating Turbulent Times with Duolingo Holy moly, the dumpster fire that is the Duolingo (NASDAQ:DUOL) legal saga just got hotter. If you snagged yourself some shares between May 2, 2025, and February 26, 2026, you'd better sit down and grab some antacids—because the nauseating roller coaster is far from over. Robbins LLP is rounding up the troops for a class action,...

Continue Reading
Daymond John's Four-Center Bet on Longevity Game

Updated Category News Views 210

A Shark's Dive into Longevity Here you go—Daymond John, the face of FUBU and a household name from Shark Tank, is not just talking about living longer; he's putting his wallet where his words are. John is jumping into the longevity game with both feet, joining Ultimate Longevity Center's (ULC) latest venture. We're talking about four new centers across California,...

Continue Reading
Tenax Class Action: Investors Alley Fight for Redress

Updated Category News Views 144

Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...

Continue Reading
Kinross Gold Fraud Lawsuit: What Shareholders Need to Know

Updated Category News Views 64

Kinross Gold's Legal Quagmire There's a fresh storm brewing for Kinross Gold Corporation (NYSE: KGC), and it ain't the kind investors enjoy riding. You see, the company is up to its neck in a class action lawsuit, courtesy of Schall, Brown & Schwartz LLP—a big-name shareholder rights litigation outfit. The gripe? Alleged securities fraud, violating §§10(b) and 20(a)...

Continue Reading
TCL Unveils Black Friday Steals on Smart Devices

Updated Category News Views 157

TCL's Big Move This Holiday Season When was the last time you saw a deal that actually made you stop and check your wallet? Well, TCL is giving you a reason to dig deep this Black Friday and Cyber Monday. They're slashing prices across smartphones and tablets, trying to elbow their way into your shopping cart with discounts up to $150. Now that's the kind of aggressive...

Continue Reading
Lilly Endowment Boosts Military Families with $10M Grant

Updated Category News Views 78

A Game-Changer for Semper Fi & America's Fund Dive in, folks. What we've got here is a hefty chunk of change — $10 million to be precise — dropped into Semper Fi & America's Fund's lap by Lilly Endowment Inc. We're talking about a grant designed to shore up the long-term support system crafted for the brave souls in military families. It’s about time a significant...

Continue Reading
Arbor Realty Trust Hit with Securities Fraud Lawsuit

Updated Category News Views 110

Snafu at Arbor Realty: Investors Rethink Strategies You know what puts a bee in my bonnet these days? Misleading statements from companies like Arbor Realty Trust, Inc. (NYSE: ABR). The news breaks that Arbor's got itself neck-deep in a class action lawsuit, courtesy of the sharp folks over at Schall, Brown & Schwartz LLP. Now, this ain't your average financial hiccup....

Continue Reading
LA Hospitals Shine in Pulmonary Excellence Nationwide

Updated Category News Views 150

Los Angeles Community Hospitals' Recent Recognition You ever stroll into a hospital and wonder if you’re really getting the best care? Well, the folks over at Los Angeles Community Hospitals, covering LA, Norwalk, and Bellflower, just got a big nod from Healthgrades—yeah, the site everyone's checking to find decent healthcare options. They’ve landed among the top...

Continue Reading

Top 5 Most Recently Viewed Articles

Atlantic International Corp. Achieves Major Contract Success

Updated Category News Views 124

Atlantic International Corp. Secures Major Contract for Growth Atlantic International Corp. (Nasdaq: ATLN), a prominent player in the field of strategic staffing, recently achieved a significant milestone through its subsidiary, Lyneer Staffing Solutions. This achievement comes in the form of a multi-million dollar manufacturing contract with a leading food manufacturer....

Continue Reading
Santa Cruz County's Bold Move Against Cigarette Filters

Updated Category News Views 144

Santa Cruz County's Bold Action Against Cigarette Filters In a landmark decision, Santa Cruz County has become the first jurisdiction globally to implement a ban on the sale of cigarettes with filters. This crucial measure aligns perfectly with the upcoming World No Tobacco Day, highlighting the county's commitment to both public health and environmental sustainability....

Continue Reading
OceanaGold Embraces New Fast-Track Approvals for Growth

Updated Category News Views 154

OceanaGold Welcomes New Fast-track Approvals Act OceanaGold Corporation (TSX: OGC) (OTCQX: OCANF) has embraced the recent passing of the Fast-track Approvals Act by the New Zealand Parliament. This important legislative move is designed to streamline the consenting process for regionally and nationally significant infrastructure and development projects. With this new...

Continue Reading
Why Debt Repayment Spreadsheets Fail and How to Get Out of Debt

Updated Category Personal Finance Views 113

We have all been told the same basic formula for clearing negative balances: list your liabilities from smallest to largest, choose between the avalanche or snowball method, and cut your spending to the bone. On paper, a debt payoff journey looks like a straightforward mathematical equation. But if you have ever spent a weekend building a beautiful, co

Continue Reading
Elis Reports Own Shares Trading Activity and Future Plans

Updated Category News Views 232

Elis Shares Trading Activity Overview Elis has recently engaged in noteworthy trading activities concerning its own shares. As part of this initiative, Elis has executed buybacks of its own shares under a designated program authorized by the company's shareholders. Details of Recent Share Buybacks According to updated regulations on share buybacks, Elis conducted several...

Continue Reading